Nordic ListingsIssuer Report
Initiator Pharma A/S: Quarterly Trading Report 2025 Q3
Initiator Pharma A/S: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=b2e25e3bba81f8dbf04c05eea97b3cbba&lang=en&src=omxlink
Initiator Pharma A/S: Quarterly Trading Report 2025 Q3
Earlier from Initiator Pharma
- INIT: Pudafensine advances to Phase II for vulvodynia, targeting major unmet needs in women's health
- INIT: Pudafensine advanced to Phase IIa for vulvodynia, with strong funding and reduced Q2 losses
- INIT: Q1 2025 saw reduced losses and clinical progress in ED, FSD, and pain programs
- INIT: Reduced losses and clinical progress in ED and FSD position Initiator Pharma for future growth
- INIT: Reduced losses and strong clinical progress for pudafensine mark Q3 2024 for Initiator Pharma
Later from Initiator Pharma
- Initiator Pharma Gets UK CTA Approval For Phase 2a Study
- INIT: First-in-class therapy for vulvodynia enters pivotal trial, targeting a multibillion-euro market
- INIT: Advanced clinical pipeline and secured major financing, with focus on vulvodynia and ED markets
- Initiator Pharma to attend J.P. Morgan Healthcare Conference in San Francisco
- Initiator Pharma Granted European Patent For Pudafensine in FSD
Follow Initiator Pharma into a list and get an email when it puts out news.
Follow Initiator Pharma